Perennial Malaria Chemoprevention in the Malaria Vaccine Era
Status:
NOT_YET_RECRUITING
Trial end date:
2033-06-01
Target enrollment:
Participant gender:
Summary
Malaria remains a major cause of pediatric deaths and morbidity in Africa. An affordable malaria vaccine, R21, is being deployed in Uganda and other African countries with high malaria transmission, but efficacy is incomplete and wanes rapidly, and R21 does not provide protection until infants complete the primary vaccination series, or \~9 months of age. The goal of this study is to see whether combining R21 vaccination with two novel perennial malaria chemoprevention regimens can enhance protection against malaria compared with R21 alone. This study will take place at Masafu General Hospital (MGH) in Busia District, a rural area in Southeastern Uganda bordering Lake Victoria.
Phase:
PHASE4
Details
Lead Sponsor:
Stanford University
Collaborators:
Infectious Diseases Research Collaboration, Uganda National Institute of Allergy and Infectious Diseases (NIAID) University of California, San Francisco
Treatments:
Amodiaquine fanasil, pyrimethamine drug combination